Viagra could be prescribed over counter to improve sales

13 April 2012

Pfizer Inc. has said it is considering an over-the-counter form of its Viagra anti-impotence drug as it faces tough competition from Eli Lilly and Co.'s longer-acting Cialis treatment.

"As with many of our products, Pfizer has routinely evaluated a number of options (for Viagra), including different formulations, new indications, over-the-counter, etc., and continues to do so," Pfizer said in a statement provided to Reuters.

It was the first time Pfizer had disclosed interest in an over-the-counter form of Viagra, a company spokeswoman said, but she declined to comment further when asked about the possible merits of a non-prescription form of the drug.

New York-based Pfizer disclosed the OTC option in response to an article in the Jan. 11 edition of The Business, a weekly British business magazine that said Pfizer sources had described such discussions.

OTC drugs typically sell for less than prescription medicines and often come in limited dosage strengths. Before approving OTC products, however, regulators pay close heed to whether patients can safely treat themselves without benefit of a doctor's advice.

Viagra carries a warning that it and similar drugs must not be used with nitrates, a class of heart drugs that can dangerously lower blood pressure if taken along with impotence pills. Some patients taking Viagra have also suffered a sudden decrease or loss of vision.

The Business article also said Pfizer was planning an oral-spray version of Viagra being developed by Novadel, a U.S.drug-delivery firm.

"However, we are not pursuing a spray version of Viagra," Pfizer said. Novadel Chief Financial Officer Michael Spicer said the report of its involvement with Pfizer was unfounded.

Viagra, which works for about four hours, had third-quarter global sales of $423 million. Its sales growth has been crimped by the growing popularity of Cialis, which works up to 36 hours.

• Sign up to news alerts from the Daily Mail here

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Sign up you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy notice .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT